Miller H
Sandoz Research Institute, East Hanover, New Jersey 07936.
Am J Hypertens. 1991 Feb;4(2 Pt 2):135S-139S. doi: 10.1093/ajh/4.2.135s.
Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race. There has been no evidence of negative inotropism, atrioventricular conduction delay, nor clinically significant changes in laboratory parameters associated with isradipine treatment. A total of 934 patients have been treated with isradipine in double-blind hypertension trials (involving 297 patients treated with placebo and 414 treated with active controls, such as hydrochlorothiazide and enalapril). Both the mean changes from baseline in diastolic and systolic blood pressures and the percentage of patients responding to treatment (blood pressure decrease of at least 10 mm Hg) were greater with isradipine than with placebo or active controls. Blood pressure response increases with increases in isradipine dose up to 10 to 15 mg daily; higher doses do not, on average, result in greater blood pressure reduction. The incidence of adverse reactions with isradipine is similar to that for active controls and slightly more than for placebo. There were fewer discontinuations with isradipine and, in addition, a decrease in the incidence of new adverse reactions with increasing duration of treatment, down to 1% at 24 months.
伊拉地平是一种新型二氢吡啶类钙拮抗剂，无论患者年龄或种族如何，在治疗高血压方面均显示出有效、安全且耐受性良好。没有证据表明伊拉地平治疗会出现负性肌力作用、房室传导延迟，也没有与伊拉地平治疗相关的实验室参数出现具有临床意义的变化。在双盲高血压试验中，共有934例患者接受了伊拉地平治疗（其中297例患者接受安慰剂治疗，414例患者接受活性对照治疗，如氢氯噻嗪和依那普利）。与安慰剂或活性对照相比，伊拉地平治疗后舒张压和收缩压较基线的平均变化以及治疗有反应的患者百分比（血压至少降低10 mmHg）均更大。每日伊拉地平剂量增加至10至15 mg时，血压反应随之增加；平均而言，更高剂量并不会导致更大程度的血压降低。伊拉地平不良反应的发生率与活性对照相似，略高于安慰剂。伊拉地平导致停药的情况较少，此外，随着治疗时间的延长，新不良反应的发生率下降，在24个月时降至1%。
